Kestra Medical Technologies, Ltd.
Cash Flow Statement
| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-44.1M | $-38.8M | $-34.2M | $-32.8M | $-25.8M | $-52.1M | $-21.5M | $-20.4M |
| Depreciation & Amortization | $2.7M | $2.3M | $2.0M | $2.4M | $2.0M | $1.8M | $1.9M | $1.9M |
| Depreciation | $2.7M | $2.3M | $2.0M | $2.4M | $2.0M | $1.8M | $1.9M | $1.9M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $9.5M | $10.3M | $10.1M | $8.7M | $4.6M | $22.3M | $459.0K | $1.1M |
| Net Cash from Operating Activities | $-32.3M | $-18.7M | $-18.4M | $-18.3M | $-26.3M | $-24.1M | $-18.0M | $-18.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $8.3M | $9.7M | $9.8M | $7.3M | $8.2M | $7.4M | $4.1M | $4.4M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-21.4M | $-172.7M | $-14.9M | $-7.4M | $-8.2M | $-7.4M | $-4.5M | $-4.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $22.5M | $-185.0K | $149.2M | $-27.0K | $-1.9M | $214.7M | $-119.0K | $-575.0K |
| Net Change in Cash | $-31.2M | $-191.6M | $115.9M | $-25.8M | $-36.4M | $183.2M | $-22.6M | $-23.1M |
| Free Cash Flow | $-40.6M | $-28.4M | $-28.2M | $-25.6M | $-34.4M | $-31.4M | $-22.1M | $-22.5M |